# Hypereosinophilia Associated With Antisynthetase Syndrome With Anti‐Ro52/PL12 Co‐Positivity: An Unusual Presentation

**Authors:** Abeline Kapuczinski, Marc Léon, Camelia Rossi, Benjamin Bondue, Nathalie Demeulenaere

PMC · DOI: 10.1002/ccr3.72096 · Clinical Case Reports · 2026-03-04

## TL;DR

This paper discusses a rare case of a condition involving high eosinophil levels and an autoimmune disease, highlighting challenges in diagnosis and disease severity.

## Contribution

The study identifies a rare association between hypereosinophilia and antisynthetase syndrome with anti-Ro52/PL12 co-positivity.

## Key findings

- Hypereosinophilia is uncommon in antisynthetase syndrome and complicates diagnosis.
- Anti-PL12's role in interstitial lung disease severity is debated but linked to a more severe disease phenotype when associated with anti-Ro52.
- African ethnicity may be a negative prognostic factor for lung disease severity.

## Abstract

Hypereosinophilia is uncommon in ASS and this presentation makes diagnosis more challenging. Anti‐PL12's role in the severity of ILD is controversial but its association with anti‐Ro52 seems to give a more serious disease phenotype. African ethnicity could be a negative prognostic factor, associated with lung disease severity.

## Linked entities

- **Proteins:** TRIM21 (tripartite motif containing 21), PL1_2 (terminase large subunit)
- **Diseases:** antisynthetase syndrome (MONDO:0019344), interstitial lung disease (MONDO:0015925)

## Full-text entities

- **Genes:** RIEG2 (Rieger syndrome 2) [NCBI Gene 6012] {aka ARS, RGS2}, PIK3C2A (phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha) [NCBI Gene 5286] {aka CPK, OCSKD, PI3-K-C2(ALPHA), PI3-K-C2A, PI3K-C2-alpha, PI3K-C2alpha}, TRIM21 (tripartite motif containing 21) [NCBI Gene 6737] {aka RNF81, RO52, Ro/SSA, SSA, SSA1, TRIM21/Ro52}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}
- **Diseases:** IIMs (MESH:D009220), ASS (MESH:D020159), eosinophilic pleural effusion (MESH:D010996), lesions (MESH:D009059), autoimmune disease (MESH:D001327), systemic lupus erythematosus (MESH:D008180), dermatomyositis (MESH:D003882), fever (MESH:D005334), muscular pain (MESH:D010146), muscle (MESH:D019042), vasculitis (MESH:D014657), muscle and joint involvement (MESH:C566343), fibrosis (MESH:D005355), myositic anomalies (MESH:D000013), Eosinophilia (MESH:D004802), asthma (MESH:D001249), dyspnea (MESH:D004417), cancer (MESH:D009369), Sjogren's syndrome (MESH:D012859), lung damage (MESH:D008171), myopathic (MESH:D009135), IPAF (MESH:D017563), Parasitic infections (MESH:D010272), allergy (MESH:D004342), RP (MESH:D011928), lung crackles (MESH:D012135), organ damage (MESH:D000092124), eosinophilic pneumonia (MESH:D011657), infectious disease (MESH:D003141), Pulmonary hypertension (MESH:D006976), CTD (MESH:D003240), hypereosinophilic syndrome (MESH:D017681), bronchiectasis (MESH:D001987), arthritis (MESH:D001168), rheumatoid arthritis (MESH:D001172), hypermetabolism (MESH:C565498), joint involvement (MESH:D007592), IIM (MESH:D056728), arthralgia (MESH:D018771), polymyositis (MESH:D017285), UCTD (MESH:D000074079), ASS (MESH:C537778)
- **Chemicals:** MTX (MESH:D008727), mPDN (MESH:D008775), Cyclophosphamide (MESH:D003520), MMF (MESH:D009173), AZA (MESH:D001379), carbon monoxide (MESH:D002248), steroid (MESH:D013256), tacrolimus (MESH:D016559), cyclosporine (MESH:D016572), Rituximab (MESH:D000069283)
- **Species:** Strongyloides (genus) [taxon 6247], Toxocara (genus) [taxon 6264], Ascaris (genus) [taxon 6251], Fasciola hepatica (liver fluke, species) [taxon 6192], Homo sapiens (human, species) [taxon 9606], Trichinella (genus) [taxon 6333]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12958324/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12958324/full.md

## References

14 references — full list in the complete paper: https://tomesphere.com/paper/PMC12958324/full.md

---
Source: https://tomesphere.com/paper/PMC12958324